Loading...
India's apixaban imports from SPAIN total $19 across 3 shipments from 1 foreign suppliers. KERN PHARMA S L leads with $19 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include INVITRO RESEARCH SOLUTIONS PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for apixaban — a concentrated sourcing relationship with select suppliers from SPAIN.
KERN PHARMA S L is the leading Apixaban supplier from SPAIN to India, with import value of $19 across 3 shipments. The top 5 suppliers — KERN PHARMA S L — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | KERN PHARMA S L | $19 | 3 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | INVITRO RESEARCH SOLUTIONS PRIVATE LIMITED | $19 | 3 | 100.0% |
SPAIN → India trade corridor intelligence
The Spain to India shipping corridor has experienced fluctuations in transit times due to global shipping challenges. Sea freight typically takes approximately 30 days, while air freight is around 7 days. Port congestion at major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra has led to occasional delays. Freight rates have been variable, influenced by global demand and supply chain disruptions. The exchange rate between the Euro and the Indian Rupee has also impacted the cost-effectiveness of imports from Spain. Importers should monitor these factors closely to optimize their logistics and cost strategies.
India's Production-Linked Incentive (PLI) scheme and other self-reliance initiatives have been designed to boost domestic manufacturing and reduce dependency on imports. These policies have led to increased scrutiny of imported pharmaceutical products, including Apixaban formulations. While the PLI scheme aims to encourage local production, it has also resulted in longer processing times for import approvals and a more competitive domestic market. Importers from Spain may face challenges in maintaining market share due to these policy shifts.
India and Spain share a robust trade relationship, with ongoing discussions to enhance cooperation in various sectors, including pharmaceuticals. While there is no specific Free Trade Agreement (FTA) between the two countries, both have expressed interest in facilitating trade through mutual recognition of Good Manufacturing Practices (GMP) and other regulatory alignments. These efforts aim to streamline the import process and ensure the availability of quality pharmaceutical products in the Indian market.
The landed cost for importing Apixaban formulations from Spain to India is calculated as follows:
This estimate is subject to change based on fluctuations in exchange rates, freight costs, and any changes in customs duties or taxes.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Apixaban into India, the foreign manufacturer must obtain an Import Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This process involves submitting an application with comprehensive product details, including composition, manufacturing process, and stability data. The application is evaluated by the Drug Controller General of India (DCGI) to ensure compliance with safety, efficacy, and quality standards. Upon approval, an Import License is issued, authorizing the importer to bring the product into the country. The registration process typically takes several months, depending on the completeness of the application and the regulatory workload. For Apixaban formulations under HS Code 30049099, specific requirements include detailed product dossiers and evidence of Good Manufacturing Practice (GMP) compliance. It's essential to ensure that all documentation is accurate and complete to avoid delays.
Imported Apixaban formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the product. Any discrepancies or failures in quality testing can lead to shipment rejection or destruction. Therefore, ensuring that all batches meet the required standards before shipment is crucial to avoid financial losses and reputational damage.
Between 2024 and 2026, the CDSCO has implemented stricter regulations for importing pharmaceutical products, including the mandatory registration and licensing of all imported drugs. This policy aims to enhance the safety and efficacy of medicines available in the Indian market. The Production-Linked Incentive (PLI) scheme introduced during this period has also impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports. While these measures aim to boost local production, they have led to increased scrutiny and longer processing times for import approvals. Importers must stay updated on these regulatory changes to ensure compliance and avoid disruptions in their supply chains.
Market demand, customs duty structure, and competitive landscape · Import duty: 17.10%
India imports finished Apixaban formulations primarily due to the availability of patented or branded products not manufactured domestically. Specific dosage forms or strengths may also be unavailable locally, necessitating imports to meet patient needs. Despite a growing domestic pharmaceutical industry, certain specialized formulations are still sourced from abroad to ensure comprehensive treatment options. The market size for Apixaban in India is substantial, with a significant volume of imports to meet the therapeutic demands of the population.
The Basic Customs Duty (BCD) for Apixaban formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Goods and Services Tax (GST) at 12% is levied on the total value, including customs duties. Therefore, the total landed cost for importing Apixaban formulations into India is calculated as follows:
This structure is subject to change based on government policies and international trade agreements.
Spain's pharmaceutical industry is renowned for its high-quality standards and compliance with international regulations. For Apixaban formulations, Spain offers specialized dosage forms and formulations that may not be available from other suppliers. While countries like China, Germany, and the United States also export pharmaceutical products to India, Spain's competitive advantage lies in its adherence to stringent quality controls and the ability to provide unique formulations tailored to specific therapeutic needs. Spain's share in India's Apixaban import market is modest but significant, reflecting its role as a reliable supplier of quality pharmaceutical products.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Apixaban formulations from Spain due to the availability of specific dosage forms and formulations not manufactured domestically. Spain's pharmaceutical industry offers high-quality products that meet international standards, ensuring efficacy and safety. The importation of these formulations is essential to provide comprehensive treatment options for patients requiring Apixaban therapy.
Compared to other sources like China, Germany, and the United States, Spain offers Apixaban formulations with a competitive edge in terms of quality and regulatory compliance. While other countries may offer lower prices, Spain's adherence to stringent quality controls and the ability to provide unique formulations tailored to specific therapeutic needs make it a preferred choice for certain products.
Importers face risks such as single-source dependency, currency fluctuations, regulatory changes, and potential shipping disruptions. Past shortages have occurred due to global supply chain issues, affecting the availability of imported pharmaceutical products. It's crucial for importers to diversify their supplier base and maintain robust contingency plans to mitigate these risks.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Apixaban suppliers from SPAIN to India include KERN PHARMA S L. The leading supplier is KERN PHARMA S L with import value of $19 USD across 3 shipments. India imported Apixaban worth $19 USD from SPAIN in total across 3 shipments.
India imported Apixaban worth $19 USD from SPAIN across 3 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Apixaban sourced from SPAIN include INVITRO RESEARCH SOLUTIONS PRIVATE LIMITED. The largest buyer is INVITRO RESEARCH SOLUTIONS PRIVATE LIMITED with $19 in imports across 3 shipments.
The total value of Apixaban imports from SPAIN to India is $19 USD, across 3 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists